Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. MYLERAN (busulfan)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MYLERAN (busulfan)

Medicine - Posted on May 10 2017 - Updated on Jun 12 2019
Active substance (DCI)
  • busulfan
history (2)
  • 12/14/16

    MYLERAN (busulfan), antineoplastic agent

    Insufficient clinical benefit in chronic myelogenous leukaemia and in conditioning regimens for stem cell transplantation MY...
    icône flèche
  • 3/15/06

    MYLERAN 2 mg, comprimé pelliculé1 flacon en verre brun de 25 comprimés Code CIP: 369 231-7 (busulfan)

    MYLERAN 2 mg, comprimé pelliculé1 flacon en verre brun de 25 comprimés Code CIP: 369 231-7 (busulfan)
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01AB01
Manufacturer
HAC PHARMA
Presentation

MYLERAN 2 mg, comprimé pelliculé (code CIS : 64700734)
1 flacon(s) en verre brun de 25 comprimé(s) - Code CIP : 34009 369 231 7 1

All our publications
    Drug therapy Hematologic cancers Transfusions, transplantations

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
yvnPnqEJDxYtNN0S